Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
Conditions: Head and Neck Squamous Cell Carcinoma; Neoadjuvant Therapy Interventions: Drug: 3cycles (Toripalimab + cetuximab); Procedure: Surgery; Radiation: Radiotherapy or chemoradiotherapy Sponsor: Wuhan Union Hospital, China Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | China Health | Erbitux | HNSCC | Hospitals | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Research